Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg...
Saved in:
Main Authors: | Iwata, Hiroji, Masuda, Norikazu, Kim, Sung-Bae, Inoue, Kenichi, Rai, Yoshiaki, Fujita, Takashi, Chiu, Joanne, Ohtani, Shoichiro, Takahashi, Masato, Miyaki, Toshiko, Lu, Yen-Shen, Xu, Binghe, Yap, Yoon Sim, Bustam, Anita Zarina, Yao, Bin, Zhang, Bo, Bryce, Richard, Chan, Arlene |
---|---|
Format: | Article |
Published: |
Future Medicine
2019
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/24103/ https://doi.org/10.2217/fon-2019-0143 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review
by: Abdul Rafar, Noor Razilah, et al.
Published: (2019) -
Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: Von Cheong, E., et al.
Published: (2021) -
Trastuzumab-decorated nanoparticles for in vitro and in vivo tumor-targeting hyperthermia of HER2+breast cancer
by: Hamzehalipour Almaki, J., et al.
Published: (2017) -
Trastuzumab-decorated nanoparticles for: In vitro and in vivo tumor-targeting hyperthermia of HER2+ breast cancer
by: Hamzehalipour Almaki, J., et al.
Published: (2017)